Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Kymera doses first patient in Phase 1 trial of oral IRAK4 degrader KT-485, earning $20M milestone from Sanofi

Company Fundamentals
09 Jun 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Kymera Therapeutics has dosed the first participant in the Phase 1 clinical trial of KT-485, an oral IRAK4 degrader, marking a key milestone under its collaboration with Sanofi. This event triggered a $20 million milestone payment from Sanofi to Kymera. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers and patients with hidradenitis suppurativa. Kymera could earn up to $975 million in future milestones as Sanofi leads development and commercialization efforts for KT-485, which targets inflammatory pathways in immune diseases.

More News (SNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App